Latest news with #VaultCRM
Korea Herald
2 days ago
- Business
- Korea Herald
Astellas Chooses Veeva Vault CRM as Global Standard
Vault CRM will support Astellas' commercial agility and execution SINGAPORE, June 5, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. "At Astellas, we discover and deliver transformative therapies for patients around the world," said Nick Eshkenazi, chief digital and transformation officer at Astellas. "Having a foundation for commercial agility and execution is crucial. Our collaboration with Veeva will provide us with technology solutions and data to enhance our agility as a company while we partner with an entity that shares our values and focus on patients." "Astellas is a leader in improving the health of people around the world through their innovative science and healthcare solutions," said Matt Farrell, president, commercial strategy at Veeva. "With Vault CRM, we are excited to deepen our partnership to support Astellas in that mission." Vault CRM addresses the industry's unique and evolving country-specific business needs and compliance requirements. It is part of the Vault CRM Suite that connects sales, marketing, and medical teams for seamless collaboration and more effective commercial execution. About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking Statements This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at
Associated Press
2 days ago
- Business
- Associated Press
Astellas Chooses Veeva Vault CRM as Global Standard
Vault CRM will support Astellas' commercial agility and execution PLEASANTON, Calif., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. 'At Astellas, we discover and deliver transformative therapies for patients around the world,' said Nick Eshkenazi, chief digital and transformation officer at Astellas. 'Having a foundation for commercial agility and execution is crucial. Our collaboration with Veeva will provide us with technology solutions and data to enhance our agility as a company while we partner with an entity that shares our values and focus on patients.' 'Astellas is a leader in improving the health of people around the world through their innovative science and healthcare solutions,' said Matt Farrell, president, commercial strategy at Veeva. 'With Vault CRM, we are excited to deepen our partnership to support Astellas in that mission.' Vault CRM addresses the industry's unique and evolving country-specific business needs and compliance requirements. It is part of the Vault CRM Suite that connects sales, marketing, and medical teams for seamless collaboration and more effective commercial execution. About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking Statements This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at Contact: Alison Borris Veeva Systems 925-226-8821 [email protected] View original content to download multimedia: SOURCE Veeva Systems
Yahoo
2 days ago
- Business
- Yahoo
Astellas Chooses Veeva Vault CRM as Global Standard
Vault CRM will support Astellas' commercial agility and execution PLEASANTON, Calif., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. "At Astellas, we discover and deliver transformative therapies for patients around the world," said Nick Eshkenazi, chief digital and transformation officer at Astellas. "Having a foundation for commercial agility and execution is crucial. Our collaboration with Veeva will provide us with technology solutions and data to enhance our agility as a company while we partner with an entity that shares our values and focus on patients." "Astellas is a leader in improving the health of people around the world through their innovative science and healthcare solutions," said Matt Farrell, president, commercial strategy at Veeva. "With Vault CRM, we are excited to deepen our partnership to support Astellas in that mission." Vault CRM addresses the industry's unique and evolving country-specific business needs and compliance requirements. It is part of the Vault CRM Suite that connects sales, marketing, and medical teams for seamless collaboration and more effective commercial execution. About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking Statements This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at Contact: Alison BorrisVeeva View original content to download multimedia: SOURCE Veeva Systems
Yahoo
29-05-2025
- Business
- Yahoo
Reasons to Retain Veeva Systems Stock in Your Portfolio for Now
Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid fourth-quarter fiscal 2025 performance and strategic deals, is expected to contribute further. However, rising operational costs remain a cause for concern. This Zacks Rank #3 (Hold) company's shares have risen 13.2% in the year-to-date period compared with 11.6% growth of the industry. The S&P 500 Composite has decreased 1.8% during the said time frame. The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $37.91 billion. The company anticipates 26.2% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 7.92%. Image Source: Zacks Investment Research Robust Product Portfolio: Veeva Systems continues to drive the migration to its next-gen Vault CRM, with 20 new customers adopting the solution in the fourth quarter, particularly small and mid-sized biotech firms preparing for commercial launches. The company expects most top 20 pharma firms to make migration decisions by fiscal 2026, ahead of the 2030 sunset of the legacy CRM. Veeva Systems has introduced AI-driven innovations like CRM Voice Control, CRM Bot and MLR Bot to enhance efficiency, compliance and automation. Meanwhile, its Clinical Development Cloud sees growing adoption, with 17 of the top 20 pharma companies using its CTMS and a ninth committing to its EDC solution. Investments in RTSM and eCOA further expand its market opportunities. Veeva Systems' Data Cloud solutions—Compass, OpenData, Link, and the new Pulse—are gaining momentum. Compass supports over 100 brands, and Pulse secured its first seven-figure deal to enhance pharma segmentation and targeting. While enterprise-wide licensing is still in the early stages, larger contracts are expected. Veeva Systems is also expanding its Safety suite, offering a fully cloud-based solution for signal detection, adverse event reporting, and regulatory compliance, with automated updates and seamless clinical integration. Strategic Deals: Veeva Systems has secured several key deals in recent months, including Boehringer Ingelheim's commitment to migrate to Veeva Vault CRM, expanding its use of Veeva Commercial Cloud and Development Cloud. Additionally, ACTO joined the Veeva AI Partner Program to enhance generative AI capabilities for field representatives in life sciences. In October, Veeva Systems and Walgreens Boots Alliance announced a long-term partnership to leverage the former's Data Cloud and Clinical Platform, aiming to improve patient outcomes by connecting the latter's community locations with diverse patient populations for easier clinical research access. Strong Q4 Results: Veeva Systems exited the third quarter of fiscal 2025 with better-than-expected results, wherein both earnings and revenues beat their respective Zacks Consensus Estimate. This uptick in both top and bottom lines and robust performance by the Subscription services segment during the quarter were impressive. The rise in Professional services and others revenues also bodes well. Per management, Veeva Systems had a strong finish to the year by strengthening its partnerships across all customer segments, from large biopharma companies to smaller biotech firms. Rising Costs: Veeva Systems has been experiencing rising operating costs over the past few months. General and administrative expenses for the fourth quarter of fiscal 2025 increased 20.6% year over year. Management expects sales and marketing expenses to increase in fiscal 2025, primarily due to employee-related expenses as the company raises its headcount to support sales and marketing efforts associated with product offerings and the continued expansion of sales capacity across all solutions. In the fiscal fourth quarter, the total operating expenses increased 9.3% year over year. Veeva Systems expects operating expenses to increase in fiscal 2025, primarily due to employee compensation-related costs. Veeva Systems is witnessing a positive estimate revision trend for fiscal 2026. In the past 60 days, the Zacks Consensus Estimate for fiscal 2026 earnings per share (EPS) has moved a cent north to $7.30. The Zacks Consensus Estimate for first-quarter fiscal 2026 revenues is pegged at $727.9 million, indicating an 11.9% improvement from the year-ago quarter's reported number. The EPS estimate for the first quarter of fiscal 2026 is pinned at $1.74, implying a 16% improvement year over year. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
VEEV Q1 Earnings Call: Revenue Miss Offset by Subscription Strength and AI Initiatives
Healthcare software provider Veeva Systems (NASDAQ:VEEV) missed Wall Street's revenue expectations in Q1 CY2025, but sales rose 16.7% year on year to $759 million. Its non-GAAP EPS of $1.97 per share was 13% above analysts' consensus estimates. Is now the time to buy VEEV? Find out in our full research report (it's free). Revenue: $759 million (16.7% year-on-year growth) Adjusted EPS: $1.97 vs analyst estimates of $1.74 (13% beat) Adjusted Operating Income: $349.9 million vs analyst estimates of $308 million (46.1% margin, 13.6% beat) Revenue Guidance for Q2 CY2025 is $767.5 million at the midpoint, above analyst estimates of $751.5 million Adjusted EPS guidance for the full year is $7.63 at the midpoint, beating analyst estimates by 4.5% Operating Margin: 30.8%, up from 23.9% in the same quarter last year Market Capitalization: $38.21 billion Veeva Systems' first quarter results reflected solid demand for its core life sciences software, with management attributing momentum to ongoing Vault CRM adoption and strong Crossix analytics growth. CEO Peter Gassner highlighted over 80 customers are now live on Vault CRM, up from a handful a year ago, describing it as 'better than Veeva CRM' due to expanded functionality and AI integration. The Crossix business benefited from customers' increasing focus on maximizing digital marketing effectiveness, with Gassner noting its rapid ROI. Management also pointed to broad-based performance across commercial and R&D segments, supported by stable renewals and expanding customer relationships. Looking ahead, Veeva's leadership expects continued growth as the company invests in AI-driven product enhancements and expands into new market segments, including a forthcoming horizontal CRM offering outside of life sciences. Gassner emphasized the company's commitment to deeply embedding AI within its core applications, predicting, 'Veeva can help increase life sciences efficiency by 15% or so with deep AI.' Management also highlighted plans to have 200 customers live on Vault CRM within a year and expressed optimism about the initial customer interest in its new AI agents and data cloud products. However, executives acknowledged persistent macroeconomic uncertainty and noted that while the current pipeline remains stable, caution is warranted for smaller biotech clients that may face funding challenges if broader conditions deteriorate. Management attributed the quarter's performance to expanded Vault CRM adoption, strong Crossix analytics growth, and early traction with AI-driven product development. Vault CRM adoption accelerates: The number of customers live on Vault CRM grew to over 80, driven both by migrations from legacy Veeva CRM and new client wins. Management cited innovation, integration of sales and marketing functions, and the roadmap for embedded AI agents as key differentiators driving customer decisions. Crossix analytics powers commercial gains: Crossix, Veeva's analytics tool for measuring digital marketing performance, saw robust demand as clients sought to optimize digital spend. The value of comprehensive Crossix deals has doubled over three years, according to Gassner, due to expanded offerings and rapid implementation timelines. AI initiatives gain momentum: Veeva AI, a suite of embedded artificial intelligence tools, is being developed to automate core industry processes such as medical, legal, and safety workflows. Management described customer feedback as highly positive and expects to introduce AI agents into products by year-end. Horizontal CRM market entry: The company is preparing to launch a CRM product targeted beyond the life sciences sector, marking a significant strategic expansion. The initial focus will be on large enterprises, with a distinct team and operating model, and management aims to secure first customers by the end of the year. Stable performance amid macro uncertainty: While acknowledging increased economic and geopolitical uncertainty, management reported no material impact on current results or pipeline. The subscription-based revenue model and mission-critical nature of Veeva's solutions provide insulation, though small biotech clients could be more exposed to funding headwinds. Veeva's guidance for the next quarter and full year is driven by continued Vault CRM migration, growing AI adoption, and an expanding product portfolio, though management remains cautious given macroeconomic uncertainty. Vault CRM and AI adoption: Management expects ongoing Vault CRM migrations and the rollout of AI agents to drive customer wins and expand existing relationships. The ability to integrate sales, marketing, and service data is viewed as a long-term differentiator. Growth in Crossix and data cloud: Crossix remains a key growth engine, with management projecting sustained double-digit expansion as clients prioritize digital marketing measurement. Early success in the data cloud business is expected to supplement this momentum. Macro and funding risks: Leadership warned that persistent uncertainty, particularly for smaller biotech customers, could delay projects or impact funding. However, Veeva's high proportion of long-term subscription contracts and focus on mission-critical applications is expected to provide resilience in most scenarios. In the coming quarters, StockStory analysts will monitor (1) the pace of Vault CRM migrations and new customer additions, (2) tangible revenue contributions and customer adoption of Veeva AI and related agents, and (3) the initial impact of the horizontal CRM launch beyond life sciences. The progress of Crossix and data cloud businesses will also be closely watched as indicators of broader market momentum. Veeva Systems currently trades at a forward price-to-sales ratio of 12.5×. In the wake of earnings, is it a buy or sell? Find out in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
